The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 5, 2008, Pages 240-241

  Donath, Marc Y ^a   Mandrup Poulsen, Thomas ^b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

APOPTOSIS; BODY MASS; CELL DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADIPOKINES; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; PROINSULIN; RECEPTORS, INTERLEUKIN-1;

EID: 42449137013     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0783     Document Type: Short Survey

References (10)

1. Donath MY et al. (2007) Cytokines and β-cell biology: from concept to clinical translation. Endocr Rev [doi:10.1210/er.2007-0033]
2. Maedler K et al. (2002) Glucose-induced β-cell production of IL1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110: 851-860
3. Ehses JA et al. (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56: 2356-2370
4. Dinarello CA (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355-1359
5. Dayer-Métroz MD et al. (1989) A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. J Autoimmun 2: 163-171
6. Larsen CM et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526
7. Kolb H and Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes? Diabetologia 48: 1038-1050
8. Spranger J et al. (2003). Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817
9. Stratton IM et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
10. Butler AE et al. (2003) β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110